scispace - formally typeset
Open AccessJournal Article

Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. I. Pharmacological and functional evidence for distinct structural subtypes.

Reads0
Chats0
TLDR
Differences observed in the pharmacological and functional properties of the Nicotinic currents imply the expression of at least three structurally distinct nicotinic acetylcholine receptor subtypes in hippocampal neurons, which may involvement in the transduction of signals is discussed.
Abstract
Nicotinic acetylcholine receptors present on cultured hippocampal neurons from fetal rats were characterized by means of whole-cell patch-clamp technique, using a number of structurally divergent agonists and highly selective antagonists. Based upon the decay kinetics of the currents elicited by 3 mM acetylcholine (ACh) and their sensitivities to agonists and antagonists, the neurons were shown to exhibit four current types, IA, IB, II and III. Rapidly decaying currents (type IA) that were blocked by alpha-bungarotoxin (10 nM), kappa-bungarotoxin (10 nM) and methyllycaconitine (MLA, 1 nM) were the most frequent and were found in 83% of the neurons tested. Type II currents (found in 5% of the neurons) were blocked by dihydro-beta-erythroidine (10 nM), and by high concentrations of MLA and kappa-bungarotoxin (100 nM each) but not by alpha-bungarotoxin (100 nM). Type III currents (elicited in 2% of the neurons) decayed slowly and were blocked by (+/-)-mecamylamine (1 microM) but not by alpha-bungarotoxin, kappa-bungarotoxin or MLA (each at 100 nM). Some of the cells (10% of the neurons) had mixed responses (named type IB), which were only partially blocked by MLA (1 nM) or dihydro-beta-erythroidine (10 nM) alone and were completely blocked by combination of the two agents. The order of potency of agonists in activating the currents was the following: for type IA, (+)-anatoxin-a >> 1,1-dimethyl-4-phenyl-piperazinium > (-)-nicotine > cystisine > ACh > carbachol > (+)-nicotine > arecoline > suberyldicholine; for type II, ACh > (+)-anatoxin-a > (-)-nicotine > 1,1-dimethyl-4-phenyl-piperazinium > carbachol > cytisine > (+)-nicotine > suberyldicholine > arecoline. Certain agonists were particularly useful in discriminating among the various types of currents: ACh, carbachol, (-)-nicotine and suberyldicholine for type II, and cytisine for type III currents. The EC50 of ACh was approximately 130 microM for type IA and approximately 2 microM for type II currents. A marked inward rectification was observed with type II, whereas type IA currents showed very little inward rectification. Differences observed in the pharmacological and functional properties of the nicotinic currents imply the expression of at least three structurally distinct nicotinic acetylcholine receptor subtypes in hippocampal neurons. The possible involvement of these currents in the transduction of signals is discussed.

read more

Citations
More filters
Journal ArticleDOI

Mammalian nicotinic acetylcholine receptors: from structure to function.

TL;DR: This review provides a comprehensive overview of the advancement of functional and genetic studies in the late 1980s and the more recent revelations of the impact that the rich diversity in function and expression of this receptor family has on neuronal and nonneuronal cells throughout the body.
Journal ArticleDOI

Hippocampal synaptic transmission enhanced by low concentrations of nicotine

TL;DR: It is proposed that nicotine from tobacco influences cognition by enhancing synaptic transmission, and a decreased efficacy of transmission may account for the deficits associated with the loss of cholinergic innervation during Alzheimer's disease.
Journal ArticleDOI

Neuronal nicotinic receptors in the human brain

TL;DR: The current knowledge on the nAChR subtypes in the human brain, their functional roles and neuropathological involvement is described.
Journal ArticleDOI

Nicotinic Receptors in the Development and Modulation of CNS Synapses

TL;DR: This work presents a new approach to evaluating the role of tobacco smoke in the development of Duchenne muscular dystrophy and suggests that smokeless tobacco may be a more effective treatment than traditional chemotherapy.
Journal ArticleDOI

Nicotine activates and desensitizes midbrain dopamine neurons

TL;DR: It is shown that the same concentration of nicotine achieved by smokers activates and desensitizes multiple nicotinic receptors thereby regulating the activity of mesolimbic dopamine neurons, which could mediate the rewarding aspects of tobacco use.
Related Papers (5)